Antivirals for COVID-19: A critical review

 
 
Penulis: Andri Frediansyah,Andri Frediansyah, Ruchi Tiwari, Khan Sharun, Kuldeep Dhama, Harapan Harapan
No specific drugs have been approved for coronavirus disease 2019 (COVID-19) to date as the development of antivirals usually requires time. Therefore, assessment and use of currently available antiviral drugs is critical for a timely response to the current pandemic. Here, we have reviewed anti-SARS-CoV-2 potencies of available antiviral drug groups such as fusion inhibitors, protease inhibitors, neuraminidase inhibitors, and M2 ion-channel protein blockers. Although clinical trials to assess the efficacy of these antivirals are ongoing, this review highlights important information including docking and modeling analyses, in vitro studies, as well as results from clinical uses of these antivirals against COVID-19 pandemic.

Clinical Epidemiology and Global Health, 2020,

DOI: 10.1016/j.cegh.2020.07.006

No. Arsip : LIPI-20200803